First National Trust’s Biogen BIIB Stock Holding History

First National Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-572	Closed	-$242K	–	297
2015 Q1	$242K	Buy	+572	New	+$225K	0.04%	243

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

First National Trust's BIIB Position: Q2 2015 in Review

First National Trust sold out of Biogen (BIIB) in Q2 2015, closing a stake of 572 shares — an estimated $242K sold.

First National Trust first reported a position in BIIB in Q1 2015 and held it in 1 quarter. The position peaked at $242K in Q1 2015. 974 funds tracked by Wall St. Rank hold BIIB as of Q2 2015.

First National Trust reported no remaining Biogen position as of Q2 2015 after selling out during the quarter.
First National Trust sold 572 Biogen shares in Q2 2015, an estimated $242K.
First National Trust first reported a position in Biogen in Q1 2015 and held it in 1 quarter.
First National Trust's Biogen position peaked at $242K in Q1 2015.
974 funds tracked by Wall St. Rank held Biogen as of Q2 2015.

Based on First National Trust's 13F filing for Q2 2015, filed 20 Jul 2015.